Breast Cancer Subscription Landing Page Oct 2025
Could estrogen protect you from breast cancer?
Your DNA might hold the answer.
Discover how the KRAS-variant can help determine if menopausal hormone therapy (MHT), formerly hormone replacement therapy (HRT), may reduce your breast cancer risk.
Women with an inherited biomarker called the KRAS-variant may be at higher risk of developing breast cancer when estrogen levels decrease—such as during menopause, after ovary removal, or when stopping menopausal hormone therapy (MHT). For some women, estrogen may play a protective role.1
Take action:
- Find out if your DNA shows that you may benefit from being on estrogen for protection.
- Use your genetics to create a breast cancer prevention plan that’s truly personal.
- Take control of your health with information that empowers personal choice.
A simple genetic test can tell you if you carry the KRAS-variant.
“For me, it’s good to know. Because the best time to fight cancer is before it’s already spread, right when it starts.”
Stephanie, breast cancer survivor
About MiraKind
MiraKind is a nonprofit organization founded by Joanne Weidhaas, M.D., Ph.D., following her co-discovery of the KRAS-variant, a novel genetic biomarker with profound implications for cancer risk, prevention, and treatment. Through ongoing research, MiraKind has identified hundreds more such variants and works to support patients and doctors in making safer, more informed treatment decisions that help avoid side effects and improve outcomes.
Why Subscribe?
Stay informed. Stay empowered.
Our free monthly newsletter brings you the latest in MiraKind’s research and beyond—and what it means for you. Learn how your genetics may impact cancer risk, prevention, and more.
What you’ll get:
- Updates on the KRAS-variant and other breakthrough discoveries
- Insights on personalized cancer treatment and prevention
- Real stories from people like you, plus expert advice you can trust
Knowledge is power—especially when it’s personal.
We respect your privacy and will never share or sell your information.
Disclaimer: Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
Reference
- McVeigh TP, Jung SY, Kerin MJ, et al. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle. 2015;14(13):2091-2099.